As we identified ERBB2 as a relevant pathway that mediates the expression of MHC-I and thereby antigen presentation in SCLC, we further investigated the impact of ERBB2 expression in SCLC patients with high tumor mutational burden (TMB). Here, ERBB2 is linked to small cell lung carcinoma.